Hong Kong Exchanges and Clearing Limited and The Stock Exchange of Hong Kong Limited take no responsibility for the contents of this announcement, make no representation as to its accuracy or completeness and expressly disclaim any liability whatsoever for any loss howsoever arising from or in reliance upon the whole or any part of the contents of this announcement.



LEPU BIOPHARMA CO., LTD.

樂普生物科技股份有限公司

(A joint stock company incorporated in the People's Republic of China with limited liability)

(Stock Code: 2157)

VOLUNTARY ANNOUNCEMENT INCLUSION OF THE COMPANY AS AN ELIGIBLE STOCK OF THE SHENZHEN-HONG KONG STOCK CONNECT

This announcement is made by Lepu Biopharma Co., Ltd. (the "Company", together with its subsidiaries, the "Group") on a voluntary basis.

The board of directors of the Company (the "Board") is pleased to announce that the Company has been selected as an eligible stock of the Shenzhen-Hong Kong Stock Connect with effect from September 5, 2022.

The Board believes that the inclusion of the shares of the Company in the trading mechanism of the Shenzhen-Hong Kong Stock Connect would allow the Company to access a broader investor base in Mainland China and increase the trading liquidity of the Company, which would further broaden its shareholder base and increase the popularity of the Company in the capital market.

The Company would like to thank the shareholders and investors of the Company for their continued support. The Company will continue to strive to develop its business and create value for its shareholders.

By order of the Board

Lepu Biopharma Co., Ltd.

Dr. Pu Zhongjie

Chairman of the Board and Executive Director

Shanghai, the PRC, September 5, 2022

As at the date of this announcement, the board of directors of the Company comprises Dr. Pu Zhongjie as chairman and executive director, Dr. Sui Ziye as executive director and chief executive officer, Dr. Hu Chaohong as executive director and co-chief executive officer, Ms. Pu Jue, Mr. Yang Hongbing and Mr. Lin Xianghong as non-executive directors, and Mr. Zhou Demin, Mr. Yang Haifeng and Mr. Fengmao Hua as independent non-executive directors.